Skip Navigation

Cardiovascular Research 1999 42(1):246-253; doi:10.1016/S0008-6363(98)00233-8
© 1999 by European Society of Cardiology
This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Paternostro, G.
Right arrow Articles by Camici, P. G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Paternostro, G.
Right arrow Articles by Camici, P. G
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1999, European Society of Cardiology

Insulin resistance in patients with cardiac hypertrophy1

Giovanni Paternostroa, Domenico Paganob, Tomaso Gnecchi-Rusconea, Robert S Bonserb and Paolo G Camicia,*

aMRC Cyclotron Unit, Imperial College School of Medicine, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
bQueen Elizabeth Hospital, Birmingham, UK

* Corresponding author. Tel.: +44-181-383-3186; fax: +44-181-383-3742. E-mail address: paolo@cu.rpms.ac.uk (P.G. Camici)

Received 28 May 1998; accepted 14 July 1998


   Abstract
Top
 Abstract
1 Introduction
 2 Methods
 3 Results
 4 Discussion
 5 Conclusions
 References
 
Objective: Animal studies suggest that left ventricular hypertrophy might be associated with insulin resistance and alterations in glucose transporters. We have previously demonstrated myocardial insulin resistance in patients with post-ischemic heart failure. The aim was to investigate whether myocardial insulin resistance could be demonstrated in human cardiac hypertrophy in the absence of hypertension, diabetes and coronary artery disease. Methods: Eleven normotensive nondiabetic patients with cardiac hypertrophy due to aortic stenosis and angiographically normal coronary arteries were compared to 11 normal volunteers. Myocardial glucose uptake (MGU) was measured with positron emission tomography and [18F]2-fluoro-2-deoxy-D-glucose during fasting (low insulinemia) or during euglycemic–hyperinsulinemic clamp (physiologic hyperinsulinemia). Myocardial biopsies were obtained in order to investigate changes in insulin-independent (GLUT-1) and insulin-dependent (GLUT-4) glucose transporters. Results: During fasting, plasma insulin (7±1 vs. 6±1 mU/l) and MGU (0.12±0.05 vs. 0.11±0.04 µmol/min/g) were comparable in patients and controls. By contrast, during clamp, MGU was markedly reduced in patients (0.48±0.02 vs. 0.70±0.03 µmol/min/g, p<0.01) despite similar plasma insulin levels (95±6 vs. 79±6 mU/l). A decreased GLUT-4/GLUT-1 ratio was shown by Western blot analysis in patients. Conclusions: Insulin resistance seems to be a feature of the hypertrophied heart even in the absence of hypertension, coronary artery disease and diabetes and may be explained, at least in part, by abnormalities in glucose transporters.

KEYWORDS Glycolysis; Heart failure; Hyertrophy; Membrane transport; Valve (disease); Positron emission tomography


   1 Introduction
Top
 Abstract
 1 Introduction
2 Methods
 3 Results
 4 Discussion
 5 Conclusions
 References
 
Whole body insulin resistance, mainly due to a decreased responsiveness to insulin of skeletal muscle [1], has been demonstrated to be associated with systemic conditions such as diabetes (both type 1 and type 2), hypertension and coronary artery disease [1]. More recently, the non-invasive measurement of myocardial uptake of the glucose analogue [18F]2-fluoro-2-deoxy-D-glucose (FDG) by positron emission tomography (PET), has made it possible to assess the presence of cardiac insulin resistance in humans. We have previously reported that insulin resistance is present in the non-infarcted myocardium of patients with previous myocardial infarction and heart failure [2]. These myocardial regions, remote from the infarct, are likely to undergo compensatory hypertrophy [3]. On the other hand, in patients with type 1 diabetes, peripheral (skeletal muscle) insulin resistance is not accompanied by a reduced cardiac FDG uptake [4, 5]. Likewise, in young subjects with mild hypertension and no cardiac hypertrophy, Nuutila et al. [6]could show skeletal but not cardiac insulin resistance.

Insulin promotes glucose uptake and decreases the utilisation of free fatty acids by the human heart [7–9]. Glucose is a particularly important substrate for the heart. It is more efficient than other substrates in terms of oxygen consumption (more ATP is synthesized per mole of oxygen consumed) and its uptake is increased in myocardial ischemia [10, 11]. In addition, glucose seems to be important for the production of ATP for ion channels and pumps [12, 13]and has an anaplerotic role, i.e. it provides oxaloacetate, thus replenishing Krebs cycle intermediates [14].

Glucose enters the cell using specific transporters [15]. There are five facilitative glucose transporters, named GLUT-1 to GLUT-5. Of these, only GLUT-1 and GLUT-4 are present in the heart. Immunofluorescence has demonstrated the presence of both on cardiac myocytes [16]. The GLUT-1 isoform, located mainly in the sarcolemmal membrane, is thought to be involved in glucose transport in the basal metabolic state. Under such conditions, less than 1% of GLUT-4 (the insulin-responsive isoform) is located in the sarcolemma [17]. After insulin stimulation, however, glucose transport is accelerated by translocating GLUT-4 from an intracellular pool to the T-tubule and sarcolemmal membrane [17, 18]. GLUT-4 levels are decreased in adipose tissue in diabetic patients [19, 20], but probably not in skeletal muscle [18]. However, it has been reported that GLUT-4 translocation is diminished in the skeletal muscle of diabetic patients [21]. Much less is known about GLUT-4 in the insulin-resistant heart. We have previously shown that a decreased expression of cardiac GLUT-4 mRNA accompanies insulin resistance in the hypertrophied heart of the spontaneously hypertensive rat [22]. In this model, increased basal deoxyglucose uptake and a reduced response to insulin could be demonstrated [22]. In a different model of cardiac hypertrophy in the rat (aortic banding), a decreased ratio of GLUT-4 to GLUT-1 mRNA expression has been reported [23].

The purpose of the present study was to establish if myocardial insulin resistance is a feature of cardiac hypertrophy in the absence of systemic conditions that are known to be associated with a reduced response to this hormone (diabetes, hypertension, coronary artery disease). Myocardial glucose uptake was estimated using PET in patients with pure aortic stenosis. Furthermore, alterations in the expression of glucose transporters, as a possible molecular basis for insulin resistance, were investigated in cardiac biopsies.


   2 Methods
Top
 Abstract
 1 Introduction
 2 Methods
3 Results
 4 Discussion
 5 Conclusions
 References
 
2.1 Study protocol
PET was used to measure myocardial blood flow and FDG uptake at two different levels of plasma insulin: a very low one corresponding to fasting conditions and a level >ten times higher during hyperinsulinemic euglycemic clamp. Five patients and five controls were studied during fasting; six patients and six controls were studied during hyperinsulinemic euglycemic clamp. The expression of the glucose transporters GLUT-1 and GLUT-4 was measured by Western blot analysis in cardiac biopsies from the patients with aortic stenosis. Additional biopsies were obtained from failing and donor hearts at the time of cardiac transplantation. The investigation conforms with the principles outlined in the Declaration of Helsinki.

2.2 Study population
2.2.1 PET
2.2.1.1 Patients
The patient population consisted of 11 normotensive, nondiabetic patients (ten men, aged 63±2 years) with pure aortic stenosis and with normal or non-significantly diseased coronary arteries, who were on the waiting list for valve replacement. All patients were in NYHA class II and no attempt was made to standardize medical therapy. Three patients were on diuretics, one was on ACE inhibitors, one was on digitalis, one was on calcium antagonists and one was on nitrates. Before the PET scan, all patients were studied by echocardiography, according to the guidelines of the American Society of Echocardiography (Esaote Biomedica SIM 7000 CFM echograph). The posterior and septal wall thickness were measured in M-mode in the left parasternal projection (at end diastole). Since these measurements never differed by more than 1 mm, thus excluding asymmetric hypertrophy, only their average thickness is reported in Section 3.

2.2.1.2 Controls
The results of the PET studies in patients were compared with those obtained in 11 healthy male volunteers (aged 47±2 years, p<0.05 vs. patients) matched for body mass index. All had a negative history for coronary artery disease, normal physical examination, resting 12 lead electrocardiogram and echocardiogram and a treadmill exercise test (Bruce protocol) negative for myocardial ischemia at high workload.

2.3 Cardiac biopsies
2.3.1 Patients
Cardiac biopsies were obtained from four of the aortic stenosis patients (all males, age 57±1 years) studied by PET, at the time of aortic valve replacement. In a separate experiment, biopsies were also obtained from five explanted hearts of patients with end stage heart failure (all males, age 45±1 years). Three of these explanted hearts were from patients with non-ischemic cardiomyopathy and two were from patients with severe coronary artery disease.

2.3.2 Controls
Cardiac biopsies were obtained from four donor hearts, at the time of heart transplant. The donors were also all males and aged 32±4 years (p<0.05 vs. patients).

2.4 Hyperinsulinemic euglycemic clamp
Before the PET scan, a 20-G polyethylene cannula was inserted in a superficial forearm vein for infusion of glucose and insulin, as described by DeFronzo et al. [24], in order to obtain a near-steady state at physiological concentration of glucose and at plasma insulin values similar to those of the post-prandial state. A second cannula was threaded retrogradely into a superficial vein of the wrist or hand that had been arterialized using a heating pad set at 50°C. At time zero, a primed-constant insulin infusion (40 mU min–1 m2 of body surface area) was started. The body surface area was calculated from the formula of Du Bois and Du Bois [25]. The prime consisted of four times the final constant rate for the first 4 min, followed by two times the constant rate for 3 min. Four min into the insulin infusion, an exogenous D-glucose infusion was started at an initial rate of 1.5 mg min–1 per kg of body weight. The plasma glucose concentration in arterialized blood was measured at baseline and then every 5 min during the clamp. The glucose infusion rate was adjusted according to the change in plasma glucose during the preceding 5 min. Samples for insulin assay were taken from the arterialized vein at 20, 40 and 60 min during the clamp.

Glucose was measured with an automatic analyser (2300Stat, Yellow Spring, USA) which required around 30 s per measurement (this is essential during the clamp because the rate of infusion has to be adjusted as quickly as possible). Insulin was measured in the Endocrinology Laboratory of Hammersmith Hospital using an immunoradiometric assay.

Under the near-steady-state conditions of euglycemic hyperinsulinemia prevailing during the second hour of an insulin clamp, the exogenous glucose infusion rate equals the total amount of glucose metabolized by all tissues and, therefore, is an index of whole-body insulin sensitivity (expressed in µmol min–1 per kg of body weight).

2.5 PET scanning and data analysis
PET scanning was carried out in all subjects, as previously reported [2]. Briefly, the optimal imaging position was determined using a 5-min rectilinear scan and a 20-min transmission scan was then performed. The blood pool was imaged by inhalation of tracer amounts of 15O-labelled carbon monoxide (C15O). Myocardial blood flow (MBF) was measured using inhaled 15O-labelled carbon dioxide (C15O2), which is rapidly converted to 15O-labelled water (H215O) by carbonic anhydrase in the lungs [26]. Myocardial glucose uptake was measured with the glucose analogue FDG. Image manipulation and kinetic analyses were performed using the ANALYZE (Version 3.0, Biodynamics Research Unit, Mayo foundation, Rochester, MN, USA) and the MATLAB (The MathWorks Inc., Natick, MA, USA) software packages, respectively. Cardiac images were resliced in the short axis view. Tissue FDG time-activity curves were analysed by using the linearized approach proposed by Patlak et al. [27]for irreversible processes. Myocardial glucose uptake (MGU) was then obtained by multiplying regional influx rates by the plasma concentration of cold glucose, assuming a lumped constant of one, and by dividing the product by the corresponding tissue fraction. This last step was performed in order to correct for partial volume effect. A conversion for millilitres to grams of perfusable tissue was made by dividing the flow and metabolic data by the tissue density (1.04 g/ml). Thus, MGU is expressed as µmol min–1 per g of water perfusable tissue.

2.6 Western blots
All cardiac biopsies were transmural, taken from the left ventricle in an area with no macroscopic signs of fibrosis. The biopsies from the explanted hearts were cut with a scalpel. The biopsies from the donor hearts and patients undergoing valve replacement were taken using a Tru-cut (Baxter) biopsy needle and were of smaller dimensions (around 30 mg). The tissue was immediately frozen in liquid nitrogen and then stored at –70°C. At the time of analysis, the samples were pulverized on dry ice with a mortar and pestle, then 100 µl of sample buffer were added to the pulverized tissue. The sample buffer contained 62.5 mM Tris, 10% glycerol, 2% sodium dodecyl sulfate (SDS), 2 mM EDTA (all from Sigma) plus the following protease inhibitors: 1 mg/ml AEBSF, 10 mg/ml E64, 1 mg/ml pepstatin (all from Boehringer Mannheim). After the addition, the tubes were quickly frozen in liquid nitrogen, then boiled and vortex-mixed repeatedly until the tissue appeared to be completely solubilized. After 5 min centrifugation at the maximum speed on an Eppendorf bench top centrifuge, the supernatant was isolated, 10 µl were used for the protein assay and the rest was frozen in liquid nitrogen and kept at –70°C. The protein content was measured using the assay of Lowry et al. [28]. For electrophoresis, β-mercaptoethanol (3% final) was added to a volume of sample equivalent to 30 µg of protein and then volumes were equalized with sample buffer containing bromophenol blue. Western blotting was performed according to standard procedures [29]. The same filter was then probed with two antibodies: anti-GLUT-4 (rabbit polyclonal, a kind gift from Dr Gwyn Gould) [30], anti-GLUT-1 (rabbit polyclonal, from Charles River Laboratories, Wilmington, MA, USA) [31]using dilutions of 1:1300 for GLUT-4 and 1:2000 for GLUT-1. Ponceau S staining of filters was used to assess total protein. Preliminary experiments were performed with control filters in order to show that the expected band (at 50 kilodaltons) was absent if the primary antibody was omitted. Immunodetection was performed with the ECL system (Amersham). After each immunodetection, the filter was stripped using a 30-min incubation in stripping buffer (100 mM β-mercaptoethanol, 2% SDS, 62.5 mM Tris, pH 6.7) and two washing in phosphate-buffered saline (PBS)–Tween at room temperature. The efficiency of stripping was checked by reprobing in the absence of primary antibody. The intensity of the bands on the autoradiography film were quantified using the image analysis program, ANALYZE.

2.7 Statistical analysis
All results are expressed as mean±standard error of the mean. The Mann-Whitney U test was used to compare mean group values, whereas paired comparisons were performed by the Wilcoxon signed-rank test. Comparisons of more than two groups were performed using the Kruskall-Wallis test. We have used these non-parametric tests because the number of subjects is limited and the assumptions on which parametric tests are based cannot be easily verified [32]. Regression analysis was performed according to standard techniques. A value of p<0.05 was considered to be statistically significant.


   3 Results
Top
 Abstract
 1 Introduction
 2 Methods
 3 Results
4 Discussion
 5 Conclusions
 References
 
3.1 Characteristics of the study population
The body mass index (weight/height [2]) was 25±1 kg/m2 in controls and 27±1 kg/m2 in patients (p=NS). The left ventricular wall thickness was 10±0.3 mm in controls and 16±0.8 mm in patients (p<0.01). There was no difference in left ventricular wall thickness between patients studied during fasting and during clamp (16±1 mm in the fasting state and 17±1.4 mm in the clamped state, p=NS). There were no significant differences between patients and controls in systolic blood pressure (126±3 mmHg in controls vs. 126±4 mmHg in patients), diastolic blood pressure (75±3 mmHg in controls vs. 74±2 mmHg in patients) and heart rate (64±2 bpm in controls vs. 71±4 bpm in patients). The baseline plasma glucose concentration was 5.0±0.2 mM in controls, and 4.6±0.2 mM in patients (p=NS). During clamp, plasma glucose levels were 6.0±0.4 and 5.5±0.2 mM (p=NS) in controls and patients, respectively. Plasma insulin was 7±1 and 6±1 mU/l (p=NS) during fasting and 79±6 and 95±6 mU/l (p=NS) during clamp, in controls and patients, respectively. The glucose metabolized by the whole body during the last 60 min of the clamp study was 37±4 µmol min–1 kg–1 in controls and 19±2 µmol min–1 kg–1 in patients (p<0.01).

3.2 Myocardial blood flow and glucose uptake (Table 1)
There was no difference amongst the four groups in terms of myocardial blood flow rates. There was also no difference in glucose uptake between patients and controls during fasting. By contrast, myocardial glucose uptake during clamp was 31% lower in patients. Thus, a 13-fold increase in plasma insulin could increase glucose uptake by 6.4-fold in controls but only four-fold in patients (Fig. 1). During clamp, cardiac glucose uptake was linearly related to whole-body glucose utilization (r=0.70, p<0.01).


View this table:
[in this window]
[in a new window]

  		Table 1 Myocardial blood flow and glucose uptake rates during fasting and during euglycemic hyperinsulinemia (clamp) in patients and controls

 

Figure 1
View larger version (12K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 1 Myocardial rates of glucose uptake are shown during fasting and during euglycemic hyperinsulinemic glucose clamp in patients with aortic stenosis and normal controls. Only during the clamp is there a significant difference between patients and normal controls. (See also Table 1).

 
3.3 Glucose transporters
In the patients with cardiac hypertrophy and aortic stenosis, the GLUT-4/GLUT-1 ratio was decreased compared to controls (1.2±0.2 vs. 2.3±0.2, p=0.009). The GLUT-4/GLUT-1 ratio was equally decreased in the explanted hearts of the patients with heart failure (1.2±0.1) compared to controls (2.6±0.3; p=0.002) (Fig. 2). When GLUT-1 and GLUT-4 were expressed as a ratio to total protein (in arbitrary density units), the changes were not significant. In patients with aortic stenosis, GLUT-4 was 1.6±0.3 vs. 2.3±0.7 in controls and GLUT-1 was 1.3±0.3 vs. 1.0±0.4 in controls. In the explanted hearts of patients with heart failure, GLUT-4 was 1.9±0.3 vs. 2.6±0.4 in controls and GLUT-1 was 1.5±0.4 vs. 1.0±0.4 in controls. The cause of heart failure did not seem to influence the GLUT-4/GLUT-1 ratio, which was 1.3±0.1 in the three patients with heart failure due to non-ischemic cardiomyopathy and 1±0.1 in the two patients with heart failure due to coronary heart disease.


Figure 2
View larger version (30K):
[in this window]
[in a new window]
[Download PowerPoint slide]
  		Fig. 2 Representative Western blots from biopsies obtained from failing explanted hearts (F) and controls (C) on the left and from hearts of aortic stenosis patients (S) and respective controls (C) on the right. The filters were probed with anti-GLUT-1 and anti-GLUT-4 antibodies. The GLUT-4/GLUT-1 ratio is reduced in both groups of patients.

 

   4 Discussion
Top
 Abstract
 1 Introduction
 2 Methods
 3 Results
 4 Discussion
5 Conclusions
 References
 
The results obtained in patients with aortic stenosis are similar to those we have previously reported in the non-infarcted myocardium of patients with post-ischemic heart failure [2]and suggest that insulin resistance accompanies cardiac hypertrophy per se, even in the absence of coronary artery disease, diabetes and/or hypertension.

4.1 Glucose transporters
We found a reduced GLUT-4/GLUT-1 protein ratio in hearts from patients with end-stage heart failure and in those with aortic stenosis and we hypothesize that this is a possible molecular basis for the cardiac insulin resistance shown by PET. This is also consistent with previous reports of lowered GLUT-4/GLUT-1 mRNA ratio in animal models of cardiac hypertrophy [22, 23]. Interestingly, transgenic mice lacking GLUT-4 expression have cardiac hypertrophy and a decreased life span [33], raising the possibility that alterations of glucose metabolism might contribute to and not simply be a consequence of cardiac disease. Furthermore, Sun et al. [34]have shown that myocardial ischemia causes translocation of GLUT-4 to the plasma membrane of cardiac myocytes, leading to increased glucose uptake. GLUT-4 depletion could therefore limit glucose availability under conditions of hypoxia and contribute to myocardial dysfunction. On the other hand, it is well known that cardiac hypertrophy is associated with the reappearance of a pattern of gene expression that is present in the fetal and newborn heart [35]. The fetal rat heart has less GLUT-4 and more GLUT-1 than the adult [36, 37]and our results are in line with the concept of re-expression of fetal genes in cardiac hypertrophy. Our finding that comparable reductions in the GLUT-4/GLUT-1 ratio could be demonstrated in biopsies from patients with cardiac diseases of different severity and etiology suggests that this might be part of a general response of the myocardium to insult. Similar cardiac isoform switches have been reported for several other proteins, including myosin heavy chain [38], Na–K-ATPase [39]and creatine kinase [40].

4.2 Myocardial blood flow and glucose uptake
Changes in blood flow could affect glucose uptake [41], but our PET measurements do not show any significant effect of insulin on myocardial blood flow during hyperinsulinemic euglycemic clamp. While there is growing evidence that insulin can act as a vasodilator in human skeletal muscle [42], several studies have shown that hyperinsulinemia has no effect on coronary blood flow in man [8, 43]or in dogs when physiological doses of insulin were applied [44].

The FDG–PET results obtained during fasting, with low plasma insulin, are different from those reported by several in vitro animal studies, both by us and by others (e.g. [22, 45]), where deoxyglucose uptake in the absence of insulin was shown to be higher in hypertrophied hearts compared to controls. No other human studies of myocardial glucose uptake in global cardiac hypertrophy have been published. An in vivo NMR animal study [46]has also reported an increase in deoxyglucose-6-phosphate accumulation in hypertrophied hearts, in the presence of low circulating insulin values. A dog model of hypertrophy secondary to aortic constriction was employed. A possible reason for the different results obtained in man is the presence of generalized metabolic alterations that occur in patients with heart failure [47], especially an increase in circulating free fatty acids, since substrate competition regulates cardiac glucose uptake [48, 49]. Alterations in fatty acid levels were however not present in the experiment of Zhang et al. [46]and this might explain why their results differed from those we report in man.

The results of our study are consistent with those of Maki et al. [50]in patients with coronary artery disease and demonstrate that, in the human heart in vivo, the increase of glucose uptake in response to insulin is much higher than that in isolated perfused hearts [45, 51–53]. A possible explanation for this difference could be that in vivo insulin-stimulated myocardial glucose uptake is not only due to stimulation of GLUT-4 translocation, but also to a decrease in circulating fatty acids [8, 54]. Furthermore, the possible limitations [55]inherent with the use of FDG for the quantitation of myocardial glucose uptake, which are discussed below, are more serious when different metabolic states are compared.

Several medications are known to affect whole body insulin resistance. ACE-inhibitors are known to improve insulin sensitivity, while other drugs (e.g. diuretics) might worsen it [56]. It might be an objective for future studies to elucidate the effects of ACE-inhibitors on cardiac insulin resistance.

4.3 Possible limitations
Heart failure and hypertrophy are accompanied by an increase in extracellular collagen deposition [57, 58]. Therefore, normalizing the Western blot results by total protein might be inappropriate. The choice of an internal control is also difficult, since it implies that the control protein is known not to be altered. Although the GLUT-4/GLUT-1 ratio provides a relative measurement, this has a clear physiological meaning and has the additional advantage of correcting for possible variations in the handling of the samples or in the efficiency of protein transfer during the blotting procedure. Any change in this ratio will influence glucose responsiveness to insulin (that is, the difference in glucose uptake between high and low insulin concentrations), but could be due to a decrease in GLUT4, an increase in GLUT1 or to both. Changes in GLUT1 and GLUT4 expressed as a ratio to total protein were not significant, but, as mentioned above, these measurements can be considered less reliable than the ratio of the two transporters. In fact, Western blots from cardiac biopsies are often quantified as a ratio of two proteins [59–62]. For ethical reasons, we could obtain only very limited amounts of tissue from donor hearts and from the hearts of patients undergoing valve replacement, therefore, we were unable to investigate this point further. However, several authors have quantified their glucose transporter measurements as a ratio of the two transporters [23, 63, 64].

It must also be noted that our control group was composed of younger individuals compared to the patient group. Indeed, in human biopsies studies using donor hearts as a control group, an age difference is difficult to avoid. However, although insulin resistance does increase with age, the age-related changes are very gradual and are only minimal between the age groups that we have studied [65].

PET allows for attenuation correction of annihilation photons, thus enabling the accurate measurement of absolute radioactivity concentration in tissues [66]. In the case of FDG measurements, however, there are some assumptions that we have discussed in detail previously [2]. Briefly, in order to account for differences in affinity between FDG and glucose, both for glucose transporters and hexokinase, the estimate of glucose uptake obtained from FDG–PET is normally divided by the so-called lumped constant [67–69]. However, studies in isolated rat hearts have shown that the lumped constant might vary under different experimental conditions [55]. Therefore, it has been recommended that PET studies of FDG uptake in the heart should be performed under controlled metabolic conditions [55, 70], as those employed in the present study. It is worth noting that the difference in myocardial glucose uptake between fasting and euglycemic clamp estimated with FDG–PET is very similar to that measured in humans during simultaneous arterial and great cardiac vein catheterization [8].


   5 Conclusions
Top
 Abstract
 1 Introduction
 2 Methods
 3 Results
 4 Discussion
 5 Conclusions
References
 
The response of glucose uptake to insulin in the hypertrophied human heart is reduced and this reduction is independent of myocardial blood flow and predisposing conditions (hypertension, coronary artery disease, diabetes). A lower GLUT-4/GLUT-1 ratio is a possible molecular basis for this decreased responsiveness. It remains to be seen if interventions that are known to improve whole body insulin resistance might have an effect on cardiac insulin resistance and the progression to heart failure.

Time for primary review 19 days.


   Acknowledgements
 
The authors wish to thank the Medical Research Council (U.K.) for financial support.


   Notes
 
1 See pages 12–14. Back


   References
Top
 Abstract
 1 Introduction
 2 Methods
 3 Results
 4 Discussion
 5 Conclusions
 References
 

  1. Ferrannini E, Natali A. Essential hypertension, metabolic disorders, and insulin resistance. Am Heart J (1991) 121:1274–1282.[CrossRef][Web of Science][Medline]
  2. Paternostro G, Camici P.G, Lammerstma A.A, et al. Cardiac and skeletal muscle insulin resistance in patients with coronary heart disease. A study with positron emission tomography. J Clin Invest (1996) 98:2094–2099.[Web of Science][Medline]
  3. Liedtke A.J, Nellis S.H, Whitesell L.F. Effects of regional ischemia on metabolic function in adjacent aerobic myocardium. J Mol Cell Cardiol (1982) 14:195–205.[CrossRef][Web of Science][Medline]
  4. Nuutila P, Knuuti J, Ruotsalainen U, et al. Insulin resistance is localized to skeletal but not heart muscle in type 1 diabetes. Am J Physiol (1993) 264:E756–E762.[Web of Science][Medline]
  5. vom Dahl J, Herman W.H, Hicks R.J, et al. Myocardial glucose uptake in patients with insulin-dependent diabetes mellitus assessed quantitatively by dynamic positron emission tomography. Circulation (1993) 88:395–404.[Abstract/Free Full Text]
  6. Nuutila P, Maki M, Laine H, et al. Insulin action on heart and skeletal muscle glucose uptake in essential hypertension. J Clin Invest (1995) 96:1003–1009.[Web of Science][Medline]
  7. Camici P, Ferrannini E, Opie L.H. Myocardial metabolism in ischemic heart disease: basic principles and application to imaging by positron emission tomography. Prog Cardiovasc Dis (1989) 32:217–238.[CrossRef][Web of Science][Medline]
  8. Ferrannini E, Santoro D, Bonadonna R, et al. Metabolic and hemodynamic effects of insulin on human hearts. Am J Physiol (1993) 264:E308–E315.[Web of Science][Medline]
  9. Rogers W.J, Russell R.O Jr., McDaniel H.G, Rackley C.E. Acute effects of glucose–insulin–potassium infusion on myocardial substrates, coronary blood flow and oxygen consumption in man. Am J Cardiol (1977) 40:421–428.[CrossRef][Web of Science][Medline]
  10. Oliver M.F, Opie L.H. Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet (1994) 343:155–158.[CrossRef][Web of Science][Medline]
  11. Camici P, Araujo L.I, Spinks T, et al. Increased uptake of 18F-fluorodeoxyglucose in postischemic myocardium of patients with exercise-induced angina. Circulation (1986) 74:81–88.[Abstract/Free Full Text]
  12. Weiss J.N, Lamp S.T. Cardiac ATP-sensitive K+ channels. Evidence for preferential regulation by glycolysis. J Gen Physiol (1989) 94:911–935.[Abstract/Free Full Text]
  13. Balaban R.S, Bader J.P. Studies on the relationship between glycolysis and (Na++K+)-ATPase in cultured cells. Biochim Biophys Acta (1984) 804:419–426.[Medline]
  14. Taegtmeyer H. Energy metabolism of the heart: from basic concepts to clinical applications. Curr Probl Cardiol (1994) 19:59–113.[Medline]
  15. Gould G.W, Bell G.I. Facilitative glucose transporters: an expanding family. Trends Biochem Sci (1990) 15:18–23.[CrossRef][Web of Science][Medline]
  16. Young L.H, Renfu Y, Russell R, et al. Low-flow ischemia leads to translocation of canine heart GLUT-4 and GLUT-1 glucose transporters to the sarcolemma in vivo. Circulation (1997) 95:415–422.[Abstract/Free Full Text]
  17. Slot J.W, Geuze H.J, Gigengack S, James D.E, Lienhard G.E. Translocation of the glucose transporter GLUT4 in cardiac myocytes of the rat. Proc Natl Acad Sci USA (1991) 88:7815–7819.[Abstract/Free Full Text]
  18. Barnard R.J, Youngren J.F. Regulation of glucose transport in skeletal muscle. FASEB J (1992) 6:3238–3244.[Abstract]
  19. Garvey W.T, Maianu L, Huecksteadt T.P, et al. Pretranslational suppression of a glucose transporter protein causes insulin resistance in adipocytes from patients with non-insulin-dependent diabetes mellitus and obesity. J Clin Invest (1991) 87:1072–1081.[Web of Science][Medline]
  20. Sinha M.K, Raineri Maldonado C, Buchanan C, et al. Adipose tissue glucose transporters in NIDDM. Decreased levels of muscle/fat isoform. Diabetes (1991) 40:472–477.[Abstract]
  21. Vogt B, Muhlbacher C, Carrascosa J, et al. Subcellular distribution of GLUT 4 in the skeletal muscle of lean type 2 (non-insulin-dependent) diabetic patients in the basal state. Diabetologia (1992) 35:456–463.[CrossRef][Web of Science][Medline]
  22. Paternostro G, Clarke K, Heath J, Seymour A.M, Radda G.K. Decreased GLUT-4 mRNA content and insulin-sensitive deoxyglucose uptake show insulin resistance in the hypertensive rat heart. Cardiovasc Res (1995) 30:205–211.[Abstract/Free Full Text]
  23. Weinberg EO, Thienelt CD, Lorell BH. Pretranslational regulation of glucose transporter isoform expression in hearts with pressure-overload left ventricular hypertrophy. Circulation 1995;92:I-385.
  24. DeFronzo R.A, Tobin J.D, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol (1979) 237:E214–E223.[Web of Science][Medline]
  25. Lentner C. Geigy scientific tables. Vol. 5. Basel: Ciba-Geigy, 1990.
  26. Araujo L.I, Lammertsma A.A, Rhodes C.G, et al. Noninvasive quantification of regional myocardial blood flow in coronary artery disease with oxygen-15-labeled carbon dioxide inhalation and positron emission tomography. Circulation (1991) 83:875–885.[Abstract/Free Full Text]
  27. Patlak C.S, Blasberg R.G, Fenstermacher J.D. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab (1983) 3:1–7.[Web of Science][Medline]
  28. Lowry O.H, Rosebrough N.J, Farr A.L, Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 193:265–275.[Free Full Text]
  29. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. New York: Cold Spring Harbor Laboratory Press, 1989.
  30. Brant A.M, McCoid S, Thomas H.M, et al. Analysis of the glucose transporter content of islet cell lines: implications for glucose-stimulated insulin release. Cell Signal (1992) 4:641–650.[CrossRef][Web of Science][Medline]
  31. Piper R.C, Hess L.J, James D.E. Differential sorting of two glucose transporters expressed in insulin-sensitive cells. Am J Physiol (1991) 260:C570–C580.[Web of Science][Medline]
  32. Armitage P, Berry G. Statistical methods in medical research. Oxford: Blackwell Scientific, 1994.
  33. Katz E.B, Stenbit A.E, Hatton K, DePinho R, Charron M.J. Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4. Nature (1995) 377:151–155.[CrossRef][Medline]
  34. Sun D, Nguyen N, DeGrado T.R, Schwaiger M, Brosius F.Cr. Ischemia induces translocation of the insulin-responsive glucose transporter GLUT4 to the plasma membrane of cardiac myocytes. Circulation (1994) 89:793–798.[Abstract/Free Full Text]
  35. Roberts R. Molecular basis of cardiology. Cambridge, MA: Blackwell Scientific, 1993.
  36. Wang C, Hu S.M. Developmental regulation in the expression of rat heart glucose transporters. Biochem Biophys Res Commun (1991) 177:1095–1100.[CrossRef][Web of Science][Medline]
  37. Santalucia T, Camps M, Castello A, et al. Developmental regulation of GLUT-1 (erythroid/Hep G2) and GLUT-4 (muscle/fat) glucose transporter expression in rat heart, skeletal muscle, and brown adipose tissue. Endocrinology (1992) 130:837–846.[Abstract/Free Full Text]
  38. Izumo S, Lompre A.M, Matsuoka R, et al. Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy. Interaction between hemodynamic and thyroid hormone-induced signals. J Clin Invest (1987) 79:970–977.[Web of Science][Medline]
  39. Charlemagne D, Orlowski J, Oliviero P, et al. Alteration of Na,K-ATPase subunit mRNA and protein levels in hypertrophied rat heart. J Biol Chem (1994) 269:1541–1547.[Abstract/Free Full Text]
  40. Ingwall J.S, Kramer M.F, Fifer M.A, et al. The creatine kinase system in normal and diseased human myocardium. N Engl J Med (1985) 313:1050–1054.[Abstract]
  41. Baron A.D, Steinberg H, Brechtel G, Johnson A. Skeletal muscle blood flow independently modulates insulin-mediated glucose uptake. Am J Physiol (1994) 266:E248–E253.[Web of Science][Medline]
  42. Laakso M, Edelman S.V, Brechtel G, Baron A.D. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest (1990) 85:1844–1852.[Web of Science][Medline]
  43. Thomassen A, Nielsen T.T, Bagger J.P, Henningsen P. Cardiac metabolic and hemodynamic effects of insulin in patients with coronary artery disease. Diabetes (1989) 38:1175–1180.[Abstract]
  44. Barrett E.J, Schwartz R.G, Francis C.K, Zaret B.L. Regulation by insulin of myocardial glucose and fatty acid metabolism in the conscious dog. J Clin Invest (1984) 74:1073–1079.[Web of Science][Medline]
  45. Taegtmeyer H, Overturf M.L. Effects of moderate hypertension on cardiac function and metabolism in the rabbit. Hypertension (1988) 11:416–4126.[Abstract/Free Full Text]
  46. Zhang J, Duncker DJ, Xu Y, et al. Glucose uptake in the severely hypertrophied left ventricle. Circulation 1993;88:I-378.
  47. Paolisso G, Gambardella A, Galzerano D, et al. Total-body and myocardial substrate oxidation in congestive heart failure. Metabolism (1994) 43:174–179.[CrossRef][Web of Science][Medline]
  48. Nuutila P, Koivisto V.A, Knuuti J, et al. Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo. J Clin Invest (1992) 89:1767–1774.[Web of Science][Medline]
  49. Randle P.J, Garland P.B, Hales C.N, Newsholme E.A. The glucose fatty-acid cycle: its role in insulin sensitivity and metabolic disturbances of diabetes mellitus. Lancet (1963) 1:785–789.[Web of Science][Medline]
  50. Maki M, Luotolahti M, Nuutila P, et al. Glucose uptake in the chronically dysfunctional but viable myocardium. Circulation (1996) 93:1658–1666.[Abstract/Free Full Text]
  51. Morgan H.E, Randle P.J, Regen D.M. Regulation of glucose uptake by muscle. 3. The effects of insulin, anoxia, salicylate and 2,4-dinitrophenol on membrane transport and intracellular phosphorylation of glucose in the isolated rat heart. Biochem J (1959) 73:573–579.[Web of Science][Medline]
  52. Neely J.R, Denton R.M, England P.J, Randle P.J. The effects of increased heart work on the tricarboxylate cycle and its interactions with glycolysis in the perfused rat heart. Biochem J (1972) 128:147–159.[Web of Science][Medline]
  53. Sugden P.H, Smith D.M. The effects of insulin on glucose uptake and lactate release in perfused working rat heart preparations. Biochem J (1982) 206:473–479.[Web of Science][Medline]
  54. Nuutila P, Knuuti M.J, Raitakari M, et al. Effect of antilipolysis on heart and skeletal muscle glucose uptake in overnight fasted humans. Am J Physiol (1994) 267:E941–E946.[Web of Science][Medline]
  55. Hariharan R, Bray M, Ganim R, et al. Fundamental limitations of [18F]2-deoxy-2-fluoro-D-glucose for assessing myocardial glucose uptake. Circulation (1995) 91:2435–2444.[Abstract/Free Full Text]
  56. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension [see comments]. N Engl J Med (1989) 321:868–873.[Abstract]
  57. Beltrami C.A, Finato N, Rocco M, et al. The cellular basis of dilated cardiomyopathy in humans. J Mol Cell Cardiol (1995) 27:291–305.[Web of Science][Medline]
  58. Beltrami C.A, Finato N, Rocco M, et al. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation (1994) 89:151–163.[Abstract/Free Full Text]
  59. Saba Z, Nassar R, Ungerleider R.M, Oakeley A.E, Anderson P.A. Cardiac troponin T isoform expression correlates with pathophysiological descriptors in patients who underwent corrective surgery for congenital heart disease. Circulation (1996) 94:472–476.[Abstract/Free Full Text]
  60. Morano I, Hadicke K, Grom S, et al. Titin, myosin light chains and C-protein in the developing and failing human heart. J Mol Cell Cardiol (1994) 26:361–368.[CrossRef][Web of Science][Medline]
  61. Reinecke H, Studer R, Vetter R, Holtz J, Drexler H. Cardiac Na/Ca exchange activity in patients with end stage heart failure. Cardiovasc Res (1996) 31:48–54.[Abstract/Free Full Text]
  62. Studer R, Reinecke H, Bilger J, et al. Gene expression of the cardiac Na–Ca exchanger in end-stage heart failure. Circ Res (1994) 75:443–453.[Abstract/Free Full Text]
  63. Schwaiger M, Sun DQ, Deeb M, et al. Expression of myocardial glucose transporter (GLUT) mRNAs in patients with advanced coronary artery disease (CAD). Circulation 1994;90:I-113.
  64. Sivitz W.I, Lee E.C. Assessment of glucose transporter gene expression using the polymerase chain reaction. Endocrinology (1991) 128:2387–2394.[Abstract/Free Full Text]
  65. DeFronzo R.A. Glucose intolerance and aging: evidence for tissue insensitivity to insulin. Diabetes (1979) 28:1095–1101.[Web of Science][Medline]
  66. Schelbert HR. Principles of positron emission tomography. In: Marcus ML, Schelbert HR, Skorton DJ, Wolf GL, editors. Cardiac imaging. Philadelphia: WB Saunders, 1991:1140–1168.
  67. Huang S.C, Williams B.A, Barrio J.R, et al. Measurement of glucose and 2-deoxy-2-[18F]fluoro-D-glucose transport and phosphorylation rates in myocardium using dual-tracer kinetic experiments. FEBS Lett (1987) 216:128–132.[CrossRef][Web of Science][Medline]
  68. Krivokapich J, Huang S.C, Selin C.E, Phelps M.E. Fluorodeoxyglucose rate constants, lumped constant, and glucose metabolic rate in rabbit heart. Am J Physiol (1987) 252:H777–H787.[Web of Science][Medline]
  69. Marshall R.C, Huang S.C, Nash W.W, Phelps M.E. Assessment of the [18F]fluorodeoxyglucose kinetic model in calculations of myocardial glucose metabolism during ischemia. J Nucl Med (1983) 24:1060–1064.[Abstract/Free Full Text]
  70. Russell R.R, Mrus J.M, Mommessin J.I, Taegtmeyer H. Compartmentation of hexokinase in rat heart. A critical factor for tracer kinetic analysis of myocardial glucose metabolism. J Clin Invest (1992) 90:1972–1977.[Web of Science][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Mol. Cell. Biol.Home page
F. Princen, E. Bard, F. Sheikh, S. S. Zhang, J. Wang, W. M. Zago, D. Wu, R. D. Trelles, B. Bailly-Maitre, C. R. Kahn, et al.
Deletion of Shp2 Tyrosine Phosphatase in Muscle Leads to Dilated Cardiomyopathy, Insulin Resistance, and Premature Death
Mol. Cell. Biol., January 15, 2009; 29(2): 378 - 388.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. C. Villa-Abrille, A. Sidor, and B. O'Rourke
Insulin Effects on Cardiac Na+/Ca2+ Exchanger Activity: ROLE OF THE CYTOPLASMIC REGULATORY LOOP
J. Biol. Chem., June 13, 2008; 283(24): 16505 - 16513.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Paternostro, G.
Right arrow Articles by Camici, P. G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Paternostro, G.
Right arrow Articles by Camici, P. G
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?